## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

FORM 4

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> SNODGRASS H. RALPH			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>VistaGen Therapeutics</u> , <u>Inc.</u> [VTGN]							ationship of Reporting k all applicable) Director	g Person(s) to Is 10% C				
(Last) C/O VISTAGEN 343 ALLERTO	(First) N THERAPEUTIC N AVENUE	(Middle) CS, INC.		3. Date of Earliest Transaction (Month/Day/Year) 12/30/2020						X P	X Officer (give title Other (specify below) below) PRES./CHIEF SCIENTIFIC OFFICER				
(Street) SOUTH SAN FRANCISCO (City)	CA (State)	94080 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indi Line) X	,				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			2. Transac Date (Month/Da		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities A Disposed Of (			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code V		Amount (A) or (D) Pri		Price	Transaction(s) (Instr. 3 and 4)				
Common Stock			12/31/2	2020		A		5,000(1)	A	\$0.4521	87,724	D			

Common Stock				/31/202	20			Α		5,000(1	<sup>1)</sup> <b>A</b>	\$0.452	1 87,	724	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned           (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, T ecurity or Exercise (Month/Day/Year) if any C				Transaction Derivat Code (Instr. Securit 8) Acquir or Disp		ivative Expiration urities (Month/Day uired (A) Disposed D) (Instr.				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		Transaction( (Instr. 4)	5)	
Stock Option (Right to Buy)	\$1.77	12/30/2020		A		150,000		(2)	12	2/30/2030	Common Stock	150,000	\$0	150,000	D	

## Explanation of Responses:

1. Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan on December 31, 2020 in a transaction exempt under Rule 16b-3(c).

2. Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date.

## /s/ Jerrold D. Dotson, Attorneyin-Fact 01/04/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.